A Letter From the Chair:
My name is Gopi Shanker and my current role is Director & Head of Psychiatry at Novartis Institutes for Biomedical Research. It is with great pleasure and enthusiasm that I invite you to join me at the Neuropsychiatric Drug Development Summit in Boston this May.
1 in 5 adults in the United States suffer from a mental health disorder each year with 1 in 25 U.S. adults experiencing a serious neuropsychiatric disorder like schizophrenia, bipolar disorder and others. Patients suffering from neuropsychiatric disorders are at a significantly increased risk for suicide, cardiovascular and metabolic diseases, are more likely to drop out of school, be unemployed, institutionalized or incarcerated! Depression is the leading cause of disability worldwide and, together with anxiety, costs the global economy a trillion dollars in lost productivity annually. Despite such staggering impact and a large unmet need, we have witnessed many Biopharmaceutical companies retreat from investing in new drug development in this field in the last 10-15 years.
Fortunately, there’s new hope for patients following recent clinical successes with Post-partum Depression and Treatment-refractory Depression. The advent of human genetics and advances in clinical research powered by large global consortia are redefining our understanding of neuropsychiatric disorders. However, it’s clear that a set of unique challenges must be overcome in order to translate these advances in genetics, disease biology and pathophysiology into therapeutics that address the unmet need in a significant way.
That’s why the focus of this conference is so important: Developing Truly Clinically Transformative Neuropsychiatric Drugs for Patients in Need. The conference is in its 3rd annual iteration and this year’s agenda focuses on the key issues that need to be addressed, including clinical trial design, for the field to succeed along with updates on new mechanisms of action and deep dives into PTSD, Schizophrenia and Substance Use disorders.
I’d strongly advise you to take a look at the event brochure to see how the agenda is tackling these very issues that we all share.
The Neuropsychiatric Drug Development Summit will offer a welcoming environment to meet colleagues, potential collaborators and partners, and will focus on the key challenges the field is encountering in real-time.
If you are or want to become a player in the Neuropsychiatric Drug Development arena, this is the conference you should attend to both learn and make valuable connections that will help drive your efforts forward and turn the promise of these therapeutics into a reality for patients.
Based on my experiences at this conference in the past, I anticipate many enlightening talks and conversations, and look forward to seeing you all this Spring.
If you’d like more information about how to get involved, please speak to the team behind the meeting and they’ll be happy to help.
Director, Head of Psychiatry
Novartis Institutes for Biomedical Research
Chairman of Neuropsychiatric Drug Development Summit
About the Neuropsychiatric Drug Development Summit:
Now in its 3rd year, the Neuropsychiatric Drug Development meeting is the definitive industry led meeting focused on unravelling the complexities of developing truly clinically transformative neuropsychiatric drugs.
Hear from new biotechs spearheading the innovation in the field and large pharma as we present the only opportunity for drug developers from across the landscape to share and gain translatable industry learning for neuropsychiatric disorders.
Why You Should Attend:
Gain an important market update on the progress of neuropsychiatric drug development through pioneering clinical case studies in schizophrenia, PTSD and addiction
Engage in critical discussions with industry experts and hear insights into tackling the fundamental and practical challenges hindering therapeutic success
Establish lasting connections with this dedicated community to accelerate your products to market and help patients in need
Why our Expert Speakers are Excited to Attend:
"We are witnessing the beginnings of a renaissance in neuropsychiatric drug development that has the potential to completely change the way we treat commonand disabling disorders like schizophrenia and depression, the first new drugs for these serious brain disorders in many decades"
- Steve Paul, Chairman of the Board, President & Chief Executive Officer, Karuna Therapeutics
"The NPD summit in 2020 is an exciting event that focuses on the current gaps and trends in Neuropsychiatric Drug Development "
- Patricio O’Donnell, Executive Medical Director, Head of Neurocircuitry Modulation Biomarkers, Takeda